Rethinking the ways in which hospitals get reimbursed and removing barriers to patient centered care are just 2 ways in which hospitals can consider moving from volume to value, said Stephen Rosenthal, senior vice president of population health management at the Montefiore Health System.
Rethinking the ways in which hospitals get reimbursed and removing barriers to patient centered care are just 2 ways in which hospitals can consider moving from volume to value, said Stephen Rosenthal, senior vice president of population health management at the Montefiore Health System.
Transcript (slightly modified)
What do you think hospitals can do to ease the transition from volume to value?
Well, I think there needs to be a rethinking of how hospitals get reimbursed. So as you move to a value based program and many of the barriers that get put in place by regulation, like denials of payment for short stay cases, like the 2 midnight rule where a patients needs to stay in the hospital 2 midnights for that to be considered an appropriated admission. Remove those hurdles, those barriers, and allow the hospital to best manage the patient and change the way you pay the hospital.
So, if short stays are something you want to avoid, shift the dollar costs in a budget neutral way to those patients that truly need to be in the hospital who have a higher case weight or intensity of services needed so that the dollars are the same but there’s a focus on the individuals who need to be in the hospital versus perhaps moving those individuals out of the hospital setting, more into an ambulatory setting by changes in the way hospitals are reimbursed. Unfortunately, most organizations react to the financial constraints more quickly sometimes than some of the more social and/or population based strategy components.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More